Page last updated: 2024-11-08

bana 113

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID446323
CHEMBL ID55440
SCHEMBL ID141675
MeSH IDM0258451

Synonyms (20)

Synonym
4-acetylamino-3-guanidino-benzoic acid
3-carbamimidamido-4-acetamidobenzoic acid
bdbm4707
chembl55440 ,
4-acetamido-3-(diaminomethyleneamino)benzoic acid
3-(2,2-diaminoimino)-4-methylcarboxamidobenzoate
benzoic acid, 4-(acetylamino)-3-[(diaminomethylene)amino]-
4-acetamido-3-guanidino-benzoic acid
bana 113
bana-113
bcx-140
1INF
SCHEMBL141675
170447-93-5
unii-v02kf5948m
benzoic acid, 4-(acetylamino)-3-((aminoiminomethyl)amino)-
v02kf5948m ,
UDQJOWCVSMIZJP-UHFFFAOYSA-N
bdbm50478626
Q27291359

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally."( Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
Babu, YS; Bantia, S; Chand, P; Chu, N; Cole, LB; Kotian, PL; Laver, WG; Montgomery, JA; Pathak, VP; Petty, SL; Shrout, DP; Walsh, DA; Walsh, GM, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, INFLUENZA VIRUS B/LEE/40 NEURAMINIDASEInfluenza B virusIC50 (µMol)10.000010.000010.000010.0000AID977608
Neuraminidase Influenza A virus (A/Wilson-Smith/1933(H1N1))IC50 (µMol)1,249,890.00000.00000.503510.0000AID381951; AID384920
NeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)10.00000.00050.976710.0000AID147337
NeuraminidaseInfluenza A virus (A/tern/Australia/G70C/1975(H11N9))IC50 (µMol)7.50002.50002.50002.5000AID1795674; AID1795675; AID1795763; AID1795764
NeuraminidaseInfluenza B virus (B/Lee/1940)IC50 (µMol)10.00000.00100.402810.0000AID147339; AID1795763; AID1795764
NeuraminidaseInfluenza B virus (B/Lee/1940)Ki0.00250.00010.00100.0025AID147478
NeuraminidaseInfluenza A virus (A/Singapore/1/1957(H2N2))IC50 (µMol)10.00000.00100.00500.0170AID1795763
Sialidase-3Homo sapiens (human)IC50 (µMol)2.50002.40005.99808.1700AID147479
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
viral release from host cellNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
carbohydrate metabolic processSialidase-3Homo sapiens (human)
ganglioside catabolic processSialidase-3Homo sapiens (human)
oligosaccharide catabolic processSialidase-3Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwaySialidase-3Homo sapiens (human)
glycosphingolipid catabolic processSialidase-3Homo sapiens (human)
negative regulation of clathrin-dependent endocytosisSialidase-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
exo-alpha-sialidase activityNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
peptidase activator activityNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
exo-alpha-sialidase activitySialidase-3Homo sapiens (human)
protein bindingSialidase-3Homo sapiens (human)
alpha-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
extracellular regionNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
lysosomal membraneSialidase-3Homo sapiens (human)
plasma membraneSialidase-3Homo sapiens (human)
caveolaSialidase-3Homo sapiens (human)
external side of plasma membraneSialidase-3Homo sapiens (human)
early endosome membraneSialidase-3Homo sapiens (human)
recycling endosome membraneSialidase-3Homo sapiens (human)
membraneSialidase-3Homo sapiens (human)
lysosomeSialidase-3Homo sapiens (human)
cytoplasmSialidase-3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1795764Neuraminidase Inhibition Assay from Article 10.1016/s0960-894x(99)00318-2: \\Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.\\1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.
AID1795675Neuraminidase Inhibition Assay from Article 10.1016/j.bmc.2005.01.042: \\Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase.\\2005Bioorganic & medicinal chemistry, Apr-01, Volume: 13, Issue:7
Synthesis and inhibitory activity of benzoic acid and pyridine derivatives on influenza neuraminidase.
AID1795674Neuraminidase Inhibition Assay from Article 10.1021/jm970479e: \\Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.\\1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
AID1795763Neuraminidase Inhibition Assay from Article 10.1016/s0968-0896(99)00197-2: \\Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.\\1999Bioorganic & medicinal chemistry, Nov, Volume: 7, Issue:11
Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.
AID203526The compound was tested in vitro for the inhibitory concentration against influenza B/Mem/89 sialidase from whole virus by fetuin assay1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
AID147333Inhibitory activity against N9 neuraminidase subtype2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes.
AID293513Inhibition of Trypanosoma cruzi recombinant Trans-sialidase at 1 mM2007Bioorganic & medicinal chemistry, Mar-01, Volume: 15, Issue:5
Benzoic acid and pyridine derivatives as inhibitors of Trypanosoma cruzi trans-sialidase.
AID147331Inhibitory activity against N2 neuraminidase subtype2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
Comparative binding energy (COMBINE) analysis of influenza neuraminidase-inhibitor complexes.
AID203525The compound was tested in vitro for the inhibitory concentration against influenza B/Mem/89 sialidase from whole virus by MUN assay1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
AID203520The compound was tested in vitro for the inhibitory concentration against influenza N2 sialidase from whole virus by fetuin assay1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
AID147479In vitro inhibitory activity against H1N9 strain of Influenza Neuraminidase (membrane)1997Journal of medicinal chemistry, Dec-05, Volume: 40, Issue:25
Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.
AID384920Inhibition of influenza virus neuraminidase2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network.
AID147337In vitro inhibitory effect on N9 Influenza A neuraminidase1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.
AID203519The compound was tested in vitro for the inhibitory concentration against influenza N2 sialidase from whole virus by MUN assay1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Structure-based inhibitors of influenza virus sialidase. A benzoic acid lead with novel interaction.
AID147339In vitro inhibitory effect on B/Lee Influenza B neuraminidase1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Design of benzoic acid inhibitors of influenza neuraminidase containing a cyclic substitution for the N-acetyl grouping.
AID381951Inhibition of Influenza A virus neuraminidase2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors.
AID147478In vitro inhibitory activity against B/Lee/40 Influenza B Neuraminidase.1999Journal of medicinal chemistry, Jul-01, Volume: 42, Issue:13
Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB1997Journal of molecular biology, Apr-04, Volume: 267, Issue:3
Guanidinobenzoic acid inhibitors of influenza virus neuraminidase.
AID1811Experimentally measured binding affinity data derived from PDB1997Journal of molecular biology, Apr-04, Volume: 267, Issue:3
Guanidinobenzoic acid inhibitors of influenza virus neuraminidase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (54.55)18.2507
2000's5 (45.45)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]